BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

ARDX

Ardelyx, Inc.
Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

Revenue, quarterly

$121M+23.8% year on year
$150M$100M$50M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 6 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

94.4%+9.6 pp year on year
100%95%90%85%80%
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 6 Aug 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$97M+7.9% year on year
$100M$50M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 6 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$18M
$100M$0−$100M−$200M
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 6 Aug 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty